CIBC Private Wealth Group’s Protalix BioTherapeutics PLX Stock Holding History

CIBC Private Wealth Group’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,500	Closed	-$5K	–	924
2019 Q3	$5K	Hold	2,500	–	–	﹤0.01%	885
2019 Q2	$12K	Hold	2,500	–	–	﹤0.01%	911
2019 Q1	$11K	Hold	2,500	–	–	﹤0.01%	921
2018 Q4	$8K	Hold	2,500	–	–	﹤0.01%	862
2018 Q3	$18K	Hold	2,500	–	–	﹤0.01%	957
2018 Q2	$11K	Hold	2,500	–	–	﹤0.01%	1541
2018 Q1	$13K	Hold	2,500	–	–	﹤0.01%	1477
2017 Q4	$17K	Buy	+2,500	New	+$16.9K	﹤0.01%	1437

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MWPCG

Measured Wealth Private Client Group Portsmouth, New Hampshire $366M AUM 21.68% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

CIBC Private Wealth Group's PLX Position: Q4 2019 in Review

CIBC Private Wealth Group sold out of Protalix BioTherapeutics (PLX) in Q4 2019, closing a stake of 2,500 shares — an estimated $5K sold.

CIBC Private Wealth Group first reported a position in PLX in Q4 2017 and held it in 8 quarters. The position peaked at $18K in Q3 2018. 15 funds tracked by Wall St. Rank hold PLX as of Q4 2019.

CIBC Private Wealth Group reported no remaining Protalix BioTherapeutics position as of Q4 2019 after selling out during the quarter.
CIBC Private Wealth Group sold 2,500 Protalix BioTherapeutics shares in Q4 2019, an estimated $5K.
CIBC Private Wealth Group first reported a position in Protalix BioTherapeutics in Q4 2017 and held it in 8 quarters.
CIBC Private Wealth Group's Protalix BioTherapeutics position peaked at $18K in Q3 2018.
15 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q4 2019.

Based on CIBC Private Wealth Group's 13F filing for Q4 2019, filed 30 Jan 2020.